Maternal immunization with RSV fusion glycoprotein vaccine and substantial protection of neonatal baboons against respiratory syncytial virus pulmonary challenge |
| |
| Affiliation: | 1. Department of Pediatrics, College of Medicine, University of Oklahoma Health Sciences Center, 1100 North Lindsay Ave., Oklahoma City, OK, 73104 USA;2. Department of Pathology, University of Oklahoma, Health Sciences Center, 1100 North Lindsay Ave., Oklahoma City, OK, 73104 USA;3. Division of Comparative Medicine, The University of Oklahoma, Health Sciences Center, 940 Stanton L. Young Blvd., Oklahoma City, OK, 73104 USA;4. Novavax, Inc., 21 Firstfield Road, Gaithersburg, MD, USA;1. Institut de la Francophonie pour la Medecine Tropicale, Lao Democratic People’s Republic;2. Lao-Lux Laboratory, Institut Pasteur du Laos, Vientiane, Lao Democratic People’s Republic;4. Department of Infection and Immunity, Luxembourg Institute of Health, Esch-sur-Alzette, Luxembourg;5. Laboratoire Nationale de Santé, Dudelange, Luxembourg;1. Jenner Institute Oxford, Old Road Campus Research Build, Roosevelt Dr, Oxford OX3 7DQ, UK;2. TB Immunology and Vaccinology Team, Department of Bacteriology, Animal and Plant Health Agency, Weybridge, Surrey KT15 3NB, UK;3. McMaster Immunology Research Centre, McMaster University, Hamilton, ON L8S 4K1, Canada;4. Institute of Biological, Environmental & Rural Sciences (IBERS), Aberystwyth University, Penglais, Aberystwyth, Ceredigion SY23 3DA, UK;1. Mayo Clinic Vaccine Research Group, Mayo Clinic, Rochester, MN 55905, USA;2. Department of Health Sciences Research, Mayo Clinic, Rochester, MN 55905, USA;3. National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta 30333, Georgia;1. Department of radiation oncology (MaastRO Lab), GROW – School for oncology and developmental biology, Maastricht university medical center, UNS 50/23, PO Box 616, 6200 MD Maastricht, The Netherlands;2. Department of internal medicine, GROW – School for oncology and developmental biology, Maastricht university medical centre, UNS 50/23, PO Box 616, 6200 MD Maastricht, The Netherlands;1. Institut Pasteur, Paris, France;2. Meade Biologics LLC, Hillsborough, NC, USA;3. Formerly Helios Klinikum Krefeld, Krefeld, Germany;1. Sigmovir Biosystems Inc., 9610 Medical Center Drive, Suite 100, Rockville, MD 20850, United States;2. Department of Microbiology and Immunology, University of Maryland School of Medicine, Baltimore, MD 21201, United States |
| |
| Abstract: | Globally, human respiratory syncytial virus (RSV) is a major cause of severe lower respiratory infection in infants and young children. There are no licensed vaccines despite the high worldwide disease burden. RSV fusion (F) glycoprotein vaccine is the most advanced candidate for maternal immunization. In this report, a baboon maternal immunization model was used to assess the immunogenicity and protection of infants against pulmonary challenge with human RSV/A. Vaccination in the third trimester produced high anti-RSV F IgG titers and virus-neutralizing antibodies. Infants born to immunized females had high levels of serum RSV antibodies that were comparable to maternal levels at birth and persisted for over 50 days with a half-life of 14–24 days. Furthermore, infants from immunized females and challenged with RSV/A were healthy, developed less severe disease, and had only mild pulmonary inflammatory changes whereas infants born to non-vaccinated females developed more severe disease with marked to moderate interstitial pneumonia, pulmonary edema, and bronchiolar obstruction. These results support the further development of the RSV F vaccine for maternal immunization. |
| |
| Keywords: | RSV F nanoparticle Vaccine Respiratory syncytial virus Maternal immunization Baboon |
| 本文献已被 ScienceDirect 等数据库收录！ |
|
